Knoa Pharma

JUN 18, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Oxycontin (REMS)

U.S. Food and Drug Administration

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for OxyContin; this is a regulatory action, not a clinical study, and does not report efficacy or comparative trial outcomes.